PMID: 3384188Jul 1, 1988Paper

Beneficial effects of verapamil in diabetic cardiomyopathy

Diabetes
N AfzalN S Dhalla

Abstract

It has been suggested that the occurrence of an intracellular Ca2+ overload may result in the development of diabetic cardiomyopathy, which is associated with depletion of high-energy phosphate stores and a derangement of ultrastructure and cardiac dysfunction. Accordingly, the effects of verapamil, a Ca2+ antagonist, on cardiac function, ultrastructure, and high-energy phosphate stores in the myocardium were evaluated in rats made diabetic by an intravenous injection of streptozocin (65 mg/kg). Four weeks after the induction of diabetes, the animals were treated with three doses (2, 4, or 8 mg.kg-1.day-1) of verapamil for 4 wk until they were used for the measurement of different parameters. Untreated diabetic animals had slower heart rates, depressed rate of contraction and rate of relaxation, lower peak left ventricular systolic pressure, and elevated left ventricular diastolic pressure. All of these changes were significantly improved in diabetic rats receiving verapamil treatment. The beneficial effects of verapamil were more evident with higher doses (8 mg.kg-1.day-1) than with the lower doses (2 mg.kg-1.day-1). The diabetic animals also showed alterations in myocardial high-energy phosphate stores and exhibited evidence ...Continue Reading

Citations

Dec 1, 1990·Annals of Medicine·M I UusitupaK E Airaksinen
Apr 22, 2011·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·G M ChenX D Liu
Oct 3, 2012·Pathophysiology : the Official Journal of the International Society for Pathophysiology·Shamarendra N SanyalKatsushige Ono
Nov 1, 1991·Journal of the American College of Cardiology·F S FeinS M Factor
Mar 24, 2012·Diabetes·Guanlan XuAnath Shalev
Dec 25, 2010·Journal of Cardiovascular Pharmacology and Therapeutics·Ramesh K GoyalNaranjan S Dhalla
Jan 1, 1990·Circulation Research·Y TairaN S Dhalla
Dec 4, 2004·American Journal of Physiology. Heart and Circulatory Physiology·Qiming ShaoNaranjan S Dhalla
Jan 31, 2002·Drugs·Steven J Lavine, Steven D Gellman
Aug 6, 2004·Endocrine Reviews·Zhi You FangThomas H Marwick
Jun 27, 2012·Molecular Pharmacology·Hyunjoo Cha-MolstadAnath Shalev
Feb 28, 2013·Heart Failure Reviews·Michael IsfortLoren E Wold
Jun 15, 1994·Molecular and Cellular Biochemistry·C BallardS Schaffer
Sep 3, 2004·Clinical Science·Sajad A HayatRayaz A Malik
Feb 26, 2013·Heart Failure Reviews·Naranjan S DhallaVijayan Elimban
May 6, 2017·Clinical Science·Mitchel TateRebecca H Ritchie
Jul 11, 2018·Nature Medicine·Fernando OvalleAnath Shalev
Apr 5, 2020·International Journal of Molecular Sciences·Naranjan S DhallaParamjit S Tappia
Feb 1, 1994·Cardiovascular Drugs and Therapy·F S Fein, E H Sonnenblick
Mar 5, 2009·American Journal of Physiology. Endocrinology and Metabolism·Junqin ChenAnath Shalev
Mar 1, 1994·The American Journal of Medicine·J LevyJ R Sowers

❮ Previous
Next ❯

Related Concepts

Related Feeds

American Diabetes Association Journals

Discover the latest diabetes research published by the journals from the American Diabetes Association.

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.